Park Medi World Ltd.
ISIN: INE119201023 • Market Cap: ₹11,686 Cr
The 5-Pillar Quality Audit for Park Medi World Ltd.
Evaluated across Profitability, Financial Health, Historical Compounding, Valuation Safety, and Ownership Governance:
1. Profitability & Capital Efficiency
Weight: 25%Measures operating margins (26.2%), Return on Capital Employed (22.2%), and equity compounding (19.2%).
2. Financial Health & Solvency
Weight: 25%Debt-to-Equity is 0.59 with comfortable interest coverage and clean working capital.
3. Growth & Compounding Track Record
Weight: 20%Historical 3Y Sales CAGR (11.6%) and 3Y PAT CAGR (8.9%).
4. Valuation Multiple & Margin of Safety
Weight: 15%Trades at P/E of 45.27 vs PEG of 3.19 and Dividend Yield of —.
5. Ownership Quality & Governance
Weight: 15%Promoter holding stands at 82.9%, backed by 9.5% institutional ownership.
Key Fundamental Strengths
Superior Capital Efficiency (ROCE: 22.2%)
Park Medi World Ltd. generates exceptional return on capital employed of 22.2%, reflecting pricing power and competitive moat.
Robust Equity Compounding (ROE: 19.2%)
Shareholder equity compounds at a healthy 19.2%, exceeding average Indian equity benchmarks.
Areas to Watch & Potential Risks
Sectoral & Macro Headwinds (Healthcare)
Subject to broader cyclical demand, raw material price shifts, and regulatory frameworks governing the Healthcare space.
Quantitative Strategy Eligibility
Checking PARKHOSPS against established Indian wealth creation frameworks:
Coffee Can Investing Framework
Passes Saurabh Mukherjea's Coffee Can rule: 10%+ sustained revenue growth and 15%+ ROCE/ROE.
Quality Factor Screener (High RoIC + Low Debt)
Scorecard of 69/100 or leverage profile sits below strict quality index hurdles.
GARP / Value-Growth Blend
Valuation multiple or return metrics require further cyclical pullback.
Healthcare Sector Peer Comparison
Compare PARKHOSPS directly against top industry peers by market capitalization:
| Company | 5-Pillar Score | Market Cap | P/E | ROCE | D/E | Scorecard |
|---|---|---|---|---|---|---|
| Park Medi World Ltd. (PARKHOSPS)Current | 69/100 | ₹11,686 Cr | 45.27 | 22.2% | 0.59 | — |
| Sun Pharmaceutical Industries Ltd. (SUNPHARMA) | 77/100 | ₹4.55 Lakh Cr | 37.65 | 20.4% | 0.05 | View |
| Divi's Laboratories Ltd. (DIVISLAB) | 73/100 | ₹2.26 Lakh Cr | 77.37 | 19.4% | 0.00 | View |
| Torrent Pharmaceuticals Ltd. (TORNTPHARM) | 64/100 | ₹1.91 Lakh Cr | 87.43 | 9.5% | 1.76 | View |
| Apollo Hospitals Enterprise Ltd. (APOLLOHOSP) | 70/100 | ₹1.27 Lakh Cr | 60.55 | 19.1% | 0.62 | View |
| Cipla Ltd. (CIPLA) | 63/100 | ₹1.14 Lakh Cr | 33.94 | 16.1% | 0.01 | View |
Frequently Asked Questions: Park Medi World Ltd.
Q:What is the 5-Pillar Fundamental Score for Park Medi World Ltd. (PARKHOSPS)?
Park Medi World Ltd. has a RupeeTools Fundamental Score of 69/100, placing it in the 'Solid & Healthy' category. Its pillar scores are: Profitability (92/100), Financial Health (68/100), Growth (62/100), Valuation (40/100), and Ownership Quality (72/100).
Q:Is PARKHOSPS fundamentally strong for long-term investment?
PARKHOSPS currently holds a moderate quality rating of 69/100. While it operates in the Healthcare sector, investors should monitor its profit margins before initiating long-term positions.
Q:Does PARKHOSPS pass the Coffee Can Investing filter?
Yes! PARKHOSPS satisfies both core pillars of Coffee Can Investing: achieving consistently high capital returns (ROCE/ROE >= 15%) alongside double-digit multi-year revenue growth.
Q:How does PARKHOSPS compare against other Healthcare peers?
Within India's Healthcare sector, PARKHOSPS trades at a P/E of 45.27 and generates an ROCE of 22.2%. Compare its 5-Pillar score of 69/100 against top sector peers like Sun Pharmaceutical Industries Ltd. (77/100), Divi's Laboratories Ltd. (73/100).
Regulatory & SEBI Research Analyst Compliance Disclaimer:
This 5-pillar fundamental score is an automated quantitative health check generated purely from historical public financial statements, corporate filings, and exchange disclosures for educational and informational purposes only. It does NOT constitute investment advice, a stock recommendation, or a solicitation to buy or sell securities. RupeeTools is not a SEBI-registered Research Analyst. Please consult a SEBI-registered financial advisor before making investment decisions.